Petra H.M. Westveer

Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial

P. Sonneveld, Bronno van der Holt, Christine M. Segeren et al. · Haematologica · 2007 · 80 citations · Full text

Medicine, Hematology, Oncology +17

Partially T-Cell–Depleted Allogeneic Stem-Cell Transplantation for First-Line Treatment of Multiple Myeloma: A Prospective Evaluation of Patients Treated in the Phase III Study HOVON 24 MM

Henk M. Lokhorst, Christine M. Segeren, Leo F. Verdonck et al. · Journal of Clinical Oncology · 2003 · 79 citations

Medicine, Hematology, Oncology +17

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

Ka Lung Wu, Berna Beverloo, Henk M. Lokhorst et al. · British Journal of Haematology · 2007 · 73 citations

Life Sciences, Genetics, Hematology +17

Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients

Hartmut Goldschmidt, Pieter Sonneveld, F. W. Cremer et al. · Annals of Hematology · 2003 · 44 citations

Medicine, Hematology, Pharmacotherapy +7

HOVON 50/GMMG-HD3-Trial: Phase III Study on the Effect of Thalidomide Combined with High Dose Melphalan in Myeloma Patients up to 65 Years.

Hartmut Goldschmidt, Pieter Sonneveld, Iris Breitkreuz et al. · Blood · 2005 · 29 citations

Medicine, Hematology, Oncology +17